Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant T-VEC in Melanoma
NCT02211131Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2015
- Primary completion
- Apr 2019
- Modality
- Oncolytic Viruses
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of talimogene laherparepvec in melanoma (2 arms), sponsored by Amgen. Primary endpoint: Recurrence-Free Survival at 24 months. Started Feb 2015; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02211131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211131.